PHARMANUTRA SPA (PHN.MI) Stock Fundamental Analysis

BIT:PHN • IT0005274094

65.5 EUR
+0.1 (+0.15%)
Last: Feb 20, 2026, 05:29 PM
Overview Stock Chart Technical Analysis Fundamental Analysis Analyst Ratings Earnings Estimates Financials Ownership
Fundamental Rating

7

Overall PHN gets a fundamental rating of 7 out of 10. We evaluated PHN against 16 industry peers in the Personal Care Products industry. PHN scores excellent points on both the profitability and health parts. This is a solid base for a good stock. While showing a medium growth rate, PHN is valued expensive at the moment. These ratings could make PHN a good candidate for quality investing.


Dividend Valuation Growth Profitability Health

9

1. Profitability

1.1 Basic Checks

  • PHN had positive earnings in the past year.
  • In the past year PHN had a positive cash flow from operations.
  • PHN had positive earnings in each of the past 5 years.
  • In the past 5 years PHN always reported a positive cash flow from operatings.
PHN.MI Yearly Net Income VS EBIT VS OCF VS FCFPHN.MI Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 10M 20M

1.2 Ratios

  • Looking at the Return On Assets, with a value of 20.17%, PHN belongs to the top of the industry, outperforming 100.00% of the companies in the same industry.
  • Looking at the Return On Equity, with a value of 36.55%, PHN belongs to the top of the industry, outperforming 100.00% of the companies in the same industry.
  • PHN has a better Return On Invested Capital (25.72%) than 100.00% of its industry peers.
  • PHN had an Average Return On Invested Capital over the past 3 years of 17.21%. This is significantly above the industry average of 10.97%.
  • The last Return On Invested Capital (25.72%) for PHN is above the 3 year average (17.21%), which is a sign of increasing profitability.
Industry RankSector Rank
ROA 20.17%
ROE 36.55%
ROIC 25.72%
ROA(3y)13.53%
ROA(5y)17.42%
ROE(3y)26.61%
ROE(5y)29.54%
ROIC(3y)17.21%
ROIC(5y)18.21%
PHN.MI Yearly ROA, ROE, ROICPHN.MI Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 10 20 30 40 50

1.3 Margins

  • Looking at the Profit Margin, with a value of 13.39%, PHN belongs to the top of the industry, outperforming 81.25% of the companies in the same industry.
  • In the last couple of years the Profit Margin of PHN has declined.
  • PHN has a better Operating Margin (21.79%) than 100.00% of its industry peers.
  • PHN's Operating Margin has been stable in the last couple of years.
  • The Gross Margin of PHN (97.13%) is better than 100.00% of its industry peers.
  • PHN's Gross Margin has been stable in the last couple of years.
Industry RankSector Rank
OM 21.79%
PM (TTM) 13.39%
GM 97.13%
OM growth 3Y-4.84%
OM growth 5Y1.01%
PM growth 3Y-10.74%
PM growth 5Y-1.82%
GM growth 3Y-0.75%
GM growth 5Y-0.04%
PHN.MI Yearly Profit, Operating, Gross MarginsPHN.MI Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 20 40 60 80

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

8

2. Health

2.1 Basic Checks

  • PHN has a Return on Invested Capital (ROIC), which is well above the Cost of Capital (WACC), which means it is creating value.
  • Compared to 1 year ago, PHN has about the same amount of shares outstanding.
  • PHN has less shares outstanding than it did 5 years ago.
  • PHN has a better debt/assets ratio than last year.
PHN.MI Yearly Shares OutstandingPHN.MI Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 2M 4M 6M 8M
PHN.MI Yearly Total Debt VS Total AssetsPHN.MI Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M 100M

2.2 Solvency

  • An Altman-Z score of 10.87 indicates that PHN is not in any danger for bankruptcy at the moment.
  • With an excellent Altman-Z score value of 10.87, PHN belongs to the best of the industry, outperforming 100.00% of the companies in the same industry.
  • The Debt to FCF ratio of PHN is 2.01, which is a good value as it means it would take PHN, 2.01 years of fcf income to pay off all of its debts.
  • With a decent Debt to FCF ratio value of 2.01, PHN is doing good in the industry, outperforming 68.75% of the companies in the same industry.
  • A Debt/Equity ratio of 0.24 indicates that PHN is not too dependend on debt financing.
  • PHN has a better Debt to Equity ratio (0.24) than 62.50% of its industry peers.
Industry RankSector Rank
Debt/Equity 0.24
Debt/FCF 2.01
Altman-Z 10.87
ROIC/WACC3.25
WACC7.92%
PHN.MI Yearly LT Debt VS Equity VS FCFPHN.MI Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 20M 40M 60M

2.3 Liquidity

  • PHN has a Current Ratio of 2.19. This indicates that PHN is financially healthy and has no problem in meeting its short term obligations.
  • PHN has a better Current ratio (2.19) than 87.50% of its industry peers.
  • A Quick Ratio of 1.86 indicates that PHN should not have too much problems paying its short term obligations.
  • PHN has a better Quick ratio (1.86) than 100.00% of its industry peers.
Industry RankSector Rank
Current Ratio 2.19
Quick Ratio 1.86
PHN.MI Yearly Current Assets VS Current LiabilitesPHN.MI Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

6

3. Growth

3.1 Past

  • The Earnings Per Share has grown by an nice 12.84% over the past year.
  • PHN shows quite a strong growth in Earnings Per Share. Measured over the last years, the EPS has been growing by 14.63% yearly.
  • The Revenue has grown by 14.35% in the past year. This is quite good.
  • PHN shows quite a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 16.59% yearly.
EPS 1Y (TTM)12.84%
EPS 3Y6.71%
EPS 5Y14.63%
EPS Q2Q%13.11%
Revenue 1Y (TTM)14.35%
Revenue growth 3Y19.25%
Revenue growth 5Y16.59%
Sales Q2Q%19.45%

3.2 Future

  • Based on estimates for the next years, PHN will show a quite strong growth in Earnings Per Share. The EPS will grow by 15.13% on average per year.
  • Based on estimates for the next years, PHN will show a quite strong growth in Revenue. The Revenue will grow by 13.74% on average per year.
EPS Next Y6.25%
EPS Next 2Y13.31%
EPS Next 3Y15.13%
EPS Next 5YN/A
Revenue Next Year14.8%
Revenue Next 2Y14.39%
Revenue Next 3Y14.28%
Revenue Next 5Y13.74%

3.3 Evolution

  • When comparing the EPS growth rate of the last years to the growth rate of the upcoming years, we see that the growth is stable.
  • When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is stable.
PHN.MI Yearly Revenue VS EstimatesPHN.MI Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 50M 100M 150M 200M 250M
PHN.MI Yearly EPS VS EstimatesPHN.MI Yearly EPS VS EstimatesYearly EPS VS Estimates 2017 2019 2020 2021 2022 2023 2024 2025 2026 2027 0.5 1 1.5 2 2.5

More info and screens

Find the best growth stocksShow best growing peers

2

4. Valuation

4.1 Price/Earnings Ratio

  • A Price/Earnings ratio of 26.10 indicates a quite expensive valuation of PHN.
  • PHN's Price/Earnings is on the same level as the industry average.
  • Compared to an average S&P500 Price/Earnings ratio of 26.99, PHN is valued at the same level.
  • A Price/Forward Earnings ratio of 26.82 indicates a quite expensive valuation of PHN.
  • Based on the Price/Forward Earnings ratio, PHN is valued a bit more expensive than the industry average as 62.50% of the companies are valued more cheaply.
  • The average S&P500 Price/Forward Earnings ratio is at 28.02. PHN is around the same levels.
Industry RankSector Rank
PE 26.1
Fwd PE 26.82
PHN.MI Price Earnings VS Forward Price EarningsPHN.MI Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 5 10 15 20 25

4.2 Price Multiples

  • PHN's Enterprise Value to EBITDA ratio is a bit more expensive when compared to the industry. PHN is more expensive than 62.50% of the companies in the same industry.
  • Based on the Price/Free Cash Flow ratio, PHN is valued a bit more expensive than the industry average as 75.00% of the companies are valued more cheaply.
Industry RankSector Rank
P/FCF 60.82
EV/EBITDA 14.59
PHN.MI Per share dataPHN.MI EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 5 10 15

4.3 Compensation for Growth

  • The high PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates an expensive valuation of the company.
  • PHN has an outstanding profitability rating, which may justify a higher PE ratio.
  • A more expensive valuation may be justified as PHN's earnings are expected to grow with 15.13% in the coming years.
PEG (NY)4.18
PEG (5Y)1.78
EPS Next 2Y13.31%
EPS Next 3Y15.13%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

6

5. Dividend

5.1 Amount

  • PHN has a Yearly Dividend Yield of 1.62%.
  • Compared to an average industry Dividend Yield of 1.52, PHN has a dividend in line with its industry peers.
  • PHN's Dividend Yield is comparable with the S&P500 average which is at 1.81.
Industry RankSector Rank
Dividend Yield 1.62%

5.2 History

  • The dividend of PHN is nicely growing with an annual growth rate of 11.21%!
Dividend Growth(5Y)11.21%
Div Incr Years0
Div Non Decr Years0

5.3 Sustainability

  • 39.70% of the earnings are spent on dividend by PHN. This is a low number and sustainable payout ratio.
  • The dividend of PHN is growing, but earnings are growing more, so the dividend growth is sustainable.
DP39.7%
EPS Next 2Y13.31%
EPS Next 3Y15.13%
PHN.MI Yearly Income VS Free CF VS DividendPHN.MI Yearly Income VS Free CF VS DividendYearly Income VS Free CF VS Dividend 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 5M -5M 10M 15M
PHN.MI Dividend Payout.PHN.MI Dividend Payout, showing the Payout Ratio.PHN.MI Dividend Payout.PayoutRetained Earnings

More info and screens

Find the best dividend stocksShow peers with best dividend

PHARMANUTRA SPA

BIT:PHN (2/20/2026, 5:29:01 PM)

65.5

+0.1 (+0.15%)

Chartmill FA Rating
GICS SectorConsumer Staples
GICS IndustryGroupHousehold & Personal Products
GICS IndustryPersonal Care Products
Earnings (Last)11-10
Earnings (Next)03-13
Inst Owners17.49%
Inst Owner ChangeN/A
Ins Owners65.02%
Ins Owner ChangeN/A
Market Cap634.04M
Revenue(TTM)180.41M
Net Income(TTM)24.16M
Analysts82.86
Price Target83.98 (28.21%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield 1.62%
Yearly Dividend0.85
Dividend Growth(5Y)11.21%
DP39.7%
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)1.65%
PT rev (3m)1.65%
EPS NQ rev (1m)0%
EPS NQ rev (3m)N/A
EPS NY rev (1m)0%
EPS NY rev (3m)0.72%
Revenue NQ rev (1m)2.53%
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)0%
Revenue NY rev (3m)0.65%
Valuation
Industry RankSector Rank
PE 26.1
Fwd PE 26.82
P/S 3.51
P/FCF 60.82
P/OCF 43.88
P/B 9.59
P/tB 15.2
EV/EBITDA 14.59
EPS(TTM)2.51
EY3.83%
EPS(NY)2.44
Fwd EY3.73%
FCF(TTM)1.08
FCFY1.64%
OCF(TTM)1.49
OCFY2.28%
SpS18.64
BVpS6.83
TBVpS4.31
PEG (NY)4.18
PEG (5Y)1.78
Graham Number19.64
Profitability
Industry RankSector Rank
ROA 20.17%
ROE 36.55%
ROCE 44.34%
ROIC 25.72%
ROICexc 34.17%
ROICexgc 53.82%
OM 21.79%
PM (TTM) 13.39%
GM 97.13%
FCFM 5.78%
ROA(3y)13.53%
ROA(5y)17.42%
ROE(3y)26.61%
ROE(5y)29.54%
ROIC(3y)17.21%
ROIC(5y)18.21%
ROICexc(3y)25.61%
ROICexc(5y)33.67%
ROICexgc(3y)43.23%
ROICexgc(5y)50.61%
ROCE(3y)29.76%
ROCE(5y)31.61%
ROICexgc growth 3Y-15.98%
ROICexgc growth 5Y-10.26%
ROICexc growth 3Y-20.69%
ROICexc growth 5Y-11.75%
OM growth 3Y-4.84%
OM growth 5Y1.01%
PM growth 3Y-10.74%
PM growth 5Y-1.82%
GM growth 3Y-0.75%
GM growth 5Y-0.04%
F-Score7
Asset Turnover1.51
Health
Industry RankSector Rank
Debt/Equity 0.24
Debt/FCF 2.01
Debt/EBITDA 0.37
Cap/Depr 112.59%
Cap/Sales 2.23%
Interest Coverage 250
Cash Conversion 33.69%
Profit Quality 43.15%
Current Ratio 2.19
Quick Ratio 1.86
Altman-Z 10.87
F-Score7
WACC7.92%
ROIC/WACC3.25
Cap/Depr(3y)763.09%
Cap/Depr(5y)544.05%
Cap/Sales(3y)14.97%
Cap/Sales(5y)11.04%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)12.84%
EPS 3Y6.71%
EPS 5Y14.63%
EPS Q2Q%13.11%
EPS Next Y6.25%
EPS Next 2Y13.31%
EPS Next 3Y15.13%
EPS Next 5YN/A
Revenue 1Y (TTM)14.35%
Revenue growth 3Y19.25%
Revenue growth 5Y16.59%
Sales Q2Q%19.45%
Revenue Next Year14.8%
Revenue Next 2Y14.39%
Revenue Next 3Y14.28%
Revenue Next 5Y13.74%
EBIT growth 1Y10.97%
EBIT growth 3Y13.47%
EBIT growth 5Y17.77%
EBIT Next Year22.16%
EBIT Next 3Y18.62%
EBIT Next 5Y9.65%
FCF growth 1Y164.53%
FCF growth 3Y1.75%
FCF growth 5Y17.94%
OCF growth 1Y18.84%
OCF growth 3Y0.14%
OCF growth 5Y11.34%

PHARMANUTRA SPA / PHN.MI FAQ

What is the fundamental rating for PHN stock?

ChartMill assigns a fundamental rating of 7 / 10 to PHN.MI.


Can you provide the valuation status for PHARMANUTRA SPA?

ChartMill assigns a valuation rating of 2 / 10 to PHARMANUTRA SPA (PHN.MI). This can be considered as Overvalued.


What is the profitability of PHN stock?

PHARMANUTRA SPA (PHN.MI) has a profitability rating of 9 / 10.


How financially healthy is PHARMANUTRA SPA?

The financial health rating of PHARMANUTRA SPA (PHN.MI) is 8 / 10.


Is the dividend of PHARMANUTRA SPA sustainable?

The dividend rating of PHARMANUTRA SPA (PHN.MI) is 6 / 10 and the dividend payout ratio is 39.7%.